Spravato® approved for treatment of depression

June 25, 2021 (last updated)

The nasal spray, Spravato® (esketamine), is covered when deemed medically necessary to treat beneficiaries with treatment-resistant depression and other US Food and Drug Administration (FDA)-approved indications, which are available in the FDA’s Risk Evaluation and Mitigation Strategy (REMS) program. This benefit is covered under the medical benefit, not pharmacy, and prior authorization is required.

To prescribe Spravato for a TRICARE beneficiary, please log in to provider self-service to request authorization and complete the pharmacy intake form

See the TRICARE Policy Manual, Chapter 7, Section 3.18 for more information.